Oculis (NASDAQ:OCS – Get Free Report) and ABVC BioPharma (NASDAQ:ABVC – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, profitability, risk and institutional ownership.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Oculis and ABVC BioPharma, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Oculis | 1 | 0 | 6 | 0 | 2.71 |
| ABVC BioPharma | 1 | 0 | 0 | 0 | 1.00 |
Oculis currently has a consensus target price of $42.33, indicating a potential upside of 104.21%. Given Oculis’ stronger consensus rating and higher probable upside, equities analysts plainly believe Oculis is more favorable than ABVC BioPharma.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Oculis | -12,915.42% | -80.82% | -61.18% |
| ABVC BioPharma | N/A | -50.42% | -27.52% |
Earnings & Valuation
This table compares Oculis and ABVC BioPharma”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Oculis | $780,000.00 | 1,392.10 | -$97.43 million | ($2.52) | -8.23 |
| ABVC BioPharma | $510,000.00 | 100.54 | -$4.90 million | ($0.20) | -10.55 |
ABVC BioPharma has lower revenue, but higher earnings than Oculis. ABVC BioPharma is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Oculis has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500. Comparatively, ABVC BioPharma has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500.
Insider and Institutional Ownership
22.3% of Oculis shares are held by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are held by institutional investors. 17.1% of ABVC BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Oculis beats ABVC BioPharma on 8 of the 14 factors compared between the two stocks.
About Oculis
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.
About ABVC BioPharma
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
